Skip to main content

February 2013 Vol 6, No 1, Special Issue

Leukemia
Initial Choice of TKI in Patients with CML Probably Not Important
Mark Knight
Read More
Drug Updates
Ponatinib: New Option for the Treatment of Adults with CML or Ph+ ALL that Is Resistant or Intolerant to Previous Therapy with Tyrosine Kinase Inhibitors
Lynne Lederman, PhD
Read More
Payers' Perspectives
New Data Presented at Highlight Challenges and Opportunities for Payers
Matthew Mitchell, PharmD, MBA, FAMCP
Read More
Multiple Myeloma
Oral Proteasome Inhibitor MLN9708 a News Maker at ASH 2012
Caroline Helwick
Read More
Multiple Myeloma
Four-Drug Induction and 2-Drug Maintenance Boost Overall Survival in Patients with Newly Diagnosed Myeloma
Audrey Andrews
Read More
Multiple Myeloma
Host Factors Important in Patients with Myeloma
Caroline Helwick
Read More
Multiple Myeloma
New Data Demonstrate Overall Survival Benefit with Pomalidomide in Advanced Myeloma
Caroline Helwick
Read More
Leukemia
Evidence Lacking for Eliminating Prophylactic Platelet Transfusions
Audrey Andrews
Read More
Lymphoma
Bendamustine plus Rituximab Noninferior to Standard Chemotherapy for Indolent Non-Hodgkin and Mantle-Cell Lymphomas
Caroline Helwick
Read More
Lymphoma
PET-Directed Approach to Treating Early-Stage Hodgkin Lymphoma Produces Excellent Outcomes
Wayne Kuznar
Read More
Page 1 of 3
Results 1 - 10 of 30